BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-295 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-295\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07514260-172@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ABBV-295: Phase 1 readout est. (NCT07514260)
DESCRIPTION:ABBV-295\, phase 1\, Obesity.\nStudy: A Study to Assess Adverse
  Events\, Tolerability\, and Pharmacokinetics of Subcutaneous Injections o
 f ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesi
 ty.\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/abbv-295#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07514260
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291232-172@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:ABBV-295: Phase 1 readout est. (NCT07291232)
DESCRIPTION:ABBV-295\, phase 1\, Obesity.\nStudy: A Study of ABBV-295 Subcu
 taneous Injections to Assess Adverse Events and Pharmacokinetics in Adult 
 Participants With Obesity\nEstimated primary completion: April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/abbv-295#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07291232
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752979-172@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ABBV-295: Phase 2 readout est. (NCT07752979)
DESCRIPTION:ABBV-295\, phase 2\, Obesity.\nStudy: Safety and Efficacy of AB
 BV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidit
 ies\nEstimated primary completion: March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abbv-295#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07752979
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933536-172@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ABBV-295: Phase 2 readout est. (NCT07933536)
DESCRIPTION:ABBV-295\, phase 2.\nStudy: A Study to Assess Targeted Therapie
 s for Treatment of Adults With Moderate to Severe Psoriasis\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/abbv-295#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07933536
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
